Details of Disease

General Information of Disease (ID: DISMOLYU)

• Disease Name: Myocardial fibrosis
• Synonyms: African endomyocardial fibrosis; obscure African cardiomyopathy; endomyocardial sclerosis
• Disease Class: BC43: Cardiomyopathy
• Definition: A disease characterized by fibrotic thickening of the endocardium, particularly the right and/or left inflow tracts. The disease often involves the atrioventricular valves, leading to valvular regurgitaion. It most commonly occurs in children living within 15 degrees of the equator.
• Disease Hierarchy:
  DISFAF31: Restrictive cardiomyopathy
  DISMOLYU: Myocardial fibrosis
• ICD Code:
  ICD-11: ICD-11: BC43.20
  ICD-10: ICD-10: I42.3, I42.4
• Disease Identifiers:
  MONDO ID: MONDO_0006746
  MESH ID: D004719
  UMLS CUI: C0553980
  MedGen ID: 107513
  HPO ID: HP:0006685
  SNOMED CT ID: 398716006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SL125	DMEIZ20	Investigative	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACE2	TTUI5H7	Strong	Biomarker	[2]
ADRB1	TTR6W5O	Strong	Biomarker	[3]
AGT	TT5C0UB	Strong	Therapeutic	[4]
CCN2	TTIL516	Strong	Biomarker	[5]
IGF2R	TTPNE41	Strong	Biomarker	[6]
UTS2	TTERU0T	Strong	Biomarker	[7]
UTS2R	TTW5UDX	Strong	Biomarker	[8]

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
COL3A1	OTT1EMLM	Strong	Biomarker	[9]
FNDC5	OT5CSK9X	Strong	Therapeutic	[4]
SIRT4	OT5S0J23	Strong	Biomarker	[10]

References

• [1] Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor. J Exp Clin Cancer Res. 2007 Sep;26(3):405-9.
• [2] Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2.Hypertension. 2009 Apr;53(4):694-700. doi: 10.1161/HYPERTENSIONAHA.108.122333. Epub 2009 Feb 16.
• [3] Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003 Oct;9(10):1300-5. doi: 10.1038/nm930. Epub 2003 Sep 14.
• [4] Irisin attenuates angiotensin II-induced cardiac fibrosis via Nrf2 mediated inhibition of ROS/ TGF1/Smad2/3 signaling axis.Chem Biol Interact. 2019 Apr 1;302:11-21. doi: 10.1016/j.cbi.2019.01.031. Epub 2019 Jan 29.
• [5] Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.Basic Res Cardiol. 2010 May;105(3):399-407. doi: 10.1007/s00395-009-0071-x. Epub 2009 Oct 23.
• [6] Overexpression of IGF-IIR regulates cardiac remodeling and aggravates high salt induced apoptosis and fibrosis in transgenic rats.Environ Toxicol. 2019 Feb;34(2):210-218. doi: 10.1002/tox.22676. Epub 2018 Nov 18.
• [7] Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.Acta Pharmacol Sin. 2007 Jan;28(1):36-43. doi: 10.1111/j.1745-7254.2007.00485.x.
• [8] Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.Peptides. 2006 Nov;27(11):2919-26. doi: 10.1016/j.peptides.2006.06.011. Epub 2006 Aug 17.
• [9] Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001 Apr;37(5):1228-33. doi: 10.1016/s0735-1097(01)01116-0.
• [10] SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity.Eur Heart J. 2017 May 7;38(18):1389-1398. doi: 10.1093/eurheartj/ehw138.